← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › QUINOLONE ANTIBACTERIALS › Fluoroquinolones
gemifloxacin
J01MA15
Adult Dosing
- Acute bacterial exacerbation of chronic bronchitis: 320 mg orally once daily for 5 days
- Community-acquired pneumonia (mild to moderate): 320 mg orally once daily for 7 days
Pediatric Dosing
- Safety and efficacy not established in patients younger than 18 years; use not recommended due to risk of arthropathy
Indications
- Acute bacterial exacerbation of chronic bronchitis
- Community-acquired pneumonia (mild to moderate, including multidrug-resistant Streptococcus pneumoniae)
Mechanism of Action
- Fluoroquinolone antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination
Contraindications
- History of hypersensitivity to gemifloxacin, other quinolones, or excipients
- History of tendinitis or tendon rupture associated with fluoroquinolones
Adverse Reactions
- Diarrhea
- Nausea
- Rash
- Headache
- Dizziness
- Elevated hepatic transaminases
- QT prolongation
- Tendonitis and tendon rupture
- Clostridioides difficile-associated diarrhea
Drug Interactions
- Antacids containing aluminum or magnesium, sucralfate, iron, and multivalent cations significantly decrease absorption; administer gemifloxacin at least 2 hours before or after
- Class IA and III antiarrhythmics (additive risk of QT prolongation)
- Corticosteroids (increased risk of tendon rupture)
- Warfarin (may enhance anticoagulant effect)
Curated Content: Needs Vetting Before Put to Clinical Use